Simulations Plus (SLP) Acquires Immunetrics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St rises as Anthropic's IPO filing sharpens focus on AI trade
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
- Stocks, bonds edge up ahead of 'formidable' week for risk
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
June 20, 2023 8:00 AM EDTAcquisition increases breadth and depth of QSP expertise and range of therapeutic applications
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (Simulations Plus), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Immunetrics, Inc. (Immunetrics), a modeling and simulation company focused on accelerating drug development in oncology, immunology, and autoimmune diseases, areas that are among the fastest growing therapeutics.
Under the terms of the Agreement, Simulations Plus agreed to pay the shareholders of Immunetrics cash... More



